Canada Antacids Market Overview, 2031

Key Insights

• According to the research report, "Canada Antacids Market Outlook, 2031," published by Bonafide Research, the Canada Antacids Market is expected to reach a market size of more than 300.8 Million by 2031.
• Heartburn and gastroesophageal reflux disease (GERD) represent a major healthcare burden in Canada. According to data from the Canadian Digestive Health Foundation (CDHF), 5 million Canadians experience heartburn or acid regurgitation at least once a week. Furthermore, up to 29% of Canadians suffer from symptoms daily or more frequently, creating a large, continuous domestic consumer base reliant on over-the-counter (OTC) acid neutralizers for non-prescription relief.
• A key clinical and market breakthrough in Canada’s acid-control space has been Health Canada's progressive approval and updated treatment guidelines surrounding raft-forming alginate barriers (e.g., Gaviscon formulations). Unlike standard antacids that simply neutralize stomach pH, alginates react with gastric acid to form a physical gel barrier floating on top of stomach contents. Canadian clinical guidelines frequently recommend alginate-antacid combinations as a preferred first-line therapy for mild-to-moderate GERD and heartburn in pregnant populations.
• Canadian consumers are increasingly migrating away from traditional chalky chewable tablets toward better-for-you digestives. The market outlook points toward rapid growth in sugar-free, low-sodium, and dye-free formulations particularly soft-chews, gummies, and liquid shots that cater to diabetic patients, fitness-conscious buyers, and consumers seeking holistic digestive health hybrids.

Market Outlook

• While brick-and-mortar retail and community pharmacies remain the primary offline sales channel for immediate heartburn relief, online pharmacies and direct-to-consumer platforms across Canada are capturing an increasing market share. The expansion of subscription-based automatic reordering for home delivery is driving recurring revenue for national brands and emerging digital wellness labels.
• Major players operating in Canada include Haleon Canada (Tums), Reckitt Benckiser Canada (Gaviscon), Bayer Canada, Sanofi Canada, and Procter & Gamble, supported by regulatory oversight from Health Canada and consumer health advocacy from the Canadian Digestive Health Foundation (CDHF) and Food, Health & Consumer Products of Canada (FHCP).

Market Dynamics

Driver: Aging demographic & high GERD prevalence
Canada’s accelerating aging population represents a major operational driver for the antacids market. With over 5 million Canadians experiencing heartburn or reflux weekly, age-related weakening of the lower esophageal sphincter combined with lifestyle factors creates continuous, non-cyclical demand for immediate-acting OTC acid remedies.
Challenge: Long-term safety concerns & regulatory classifications
Heavy reliance on OTC antacids presents health risks, including hypercalcemia, milk-alkali syndrome, and sodium loading in cardiovascular patients. Additionally, Health Canada’s strict regulatory differentiation between over-the-counter acid neutralizers and prescription-strength acid suppressants limits manufacturers from making broad long-term therapeutic claims on packaging.
Trend: Rise of botanical hybrids & gummy delivery formats
Canadian consumers are increasingly shifting toward non-traditional formats like flavor-enhanced chewables, soft-chews, and gummies. To capture wellness-minded demographics, brands are formulating hybrid products that pair active minerals (e.g., calcium carbonate) with botanical extracts like ginger, chamomile, or peppermint for holistic digestive care.

Procurement and Industry Impact

• Chewable and traditional solid tablets comprise over 50% of finished product volume due to consumer preference for waterless, on-the-go relief. However, fast growth in alginate raft-forming liquids (such as Gaviscon formulations) requires specialized high-shear liquid compounding equipment and specialized leak-proof packaging formats.
• Brick-and-mortar retail and community pharmacies remain the dominant sales channel in Canada, accounting for over 50% of OTC distribution. To secure prime shelf space in major Canadian chains (e.g., Shoppers Drug Mart, Rexall), manufacturers allocate significant trade allowances and placement fees, impacting net margins across product lines.

Segment Analysis

Canada Antacids Market By Drug Class
• Acid neutralizers remain central to Canada's self-care gastrointestinal category because they directly neutralize excess stomach acid and are positioned for rapid relief of heartburn, acid indigestion and upset stomach. Health Canada's antacid labelling standard specifically recognizes ingredients such as aluminum hydroxide, magnesium compounds and calcium carbonate, while permitting formulations in single- or multiple-ingredient combinations.
• Proton Pump Inhibitors (PPIs) occupy a more treatment-oriented position because they suppress acid production rather than simply neutralizing acid already present in the stomach. Health Canada recognizes PPIs for conditions including heartburn/GERD and peptic ulcers. Most PPIs have historically been prescription products in Canada, although some omeprazole products are available without prescription, creating a more differentiated OTC-versus-prescription landscape than conventional antacids. Health Canada reported more than 33 million PPI prescriptions dispensed in Canada in 2016, demonstrating their substantial role in acid-related therapy.
• H2 antagonists provide an intermediate acid-control approach by reducing gastric acid secretion rather than directly neutralizing existing acid. Their positioning is particularly relevant for consumers seeking longer-lasting control of recurring symptoms. In the Canadian market, this class also operates within a regulatory environment in which the availability and sale conditions of non-prescription medicines can vary by product and provincial or territorial requirements.
• Pro-motility agents represent a specialized gastrointestinal-treatment segment rather than a conventional antacid category. Their therapeutic role focuses on gastrointestinal movement and gastric emptying, making them more relevant to selected patients with motility-related symptoms or reflux associated with impaired gastrointestinal function. Their clinical positioning means that they are less dependent on routine consumer self-selection than conventional Canadian OTC antacids.
• Combination formulations have particular relevance in Canada because Health Canada's antacid standard explicitly permits certain antacid/non-antacid combinations, including antacid products containing alginic acid/alginates or simethicone. This supports multi-symptom positioning, such as combining acid relief with reflux-barrier or gas-relief functionality. A Health Canada-approved product, for example, combines aluminum hydroxide, magnesium hydroxide and simethicone in a non-prescription liquid formulation.

Canada Antacids Market By Dosage Form
• Tablets and chewables remain highly suitable for Canadian consumers seeking convenient, portable treatment. Calcium-carbonate chewables are an established format, and Health Canada's product database includes authorized antacid tablets containing calcium carbonate. The format supports easy unit-based dosing and is particularly convenient for use after meals, while travelling or away from home.
• Liquid suspensions provide an alternative for consumers who prefer liquids or have difficulty swallowing solid dosage forms. Canada's Health Canada antacid standard specifically includes suspensions and liquids among recognized dosage forms. Liquid formulations also allow manufacturers to combine multiple active ingredients, as demonstrated by Canadian non-prescription products containing aluminum hydroxide, magnesium hydroxide and simethicone.
• Powders offer a flexible dosage approach and are specifically recognized within Canada's antacid labelling framework. Their appeal comes from the ability to prepare the product at the point of use and potentially achieve rapid dispersion. However, preparation requirements and moisture sensitivity can make packaging and consumer instructions particularly important.
• Gels and syrups are suited to consumers who prefer smooth, easy-to-swallow formulations. Health Canada's antacid standard explicitly recognizes gels and liquids among acceptable dosage forms, creating regulatory support for a diverse liquid-format product landscape. Sensory factors such as flavour, texture and mouthfeel can be important differentiators in these products because they are intended for direct oral consumption.
• Gummies and other formats represent a more consumer-oriented approach to gastrointestinal self-care. Gummies can provide portability and an approachable administration experience, but formulation developers must accommodate the relatively high active-ingredient quantities traditionally associated with antacid therapy. Other formats, including effervescent tablets, are also recognized within Health Canada's antacid framework, giving manufacturers additional opportunities to differentiate administration and consumer experience.

Canada Antacids Market By Indication
• Gastroesophageal Reflux Disease (GERD) is an important indication for Canada's broader acid-control market because treatment may involve antacids, alginate-based products, H2 antagonists or PPIs depending on symptom pattern and clinical requirements. Health Canada recognizes PPIs for heartburn/GERD, while its antacid framework permits alginate-containing products for heartburn associated with backward flow of stomach acid.
• Heartburn is the most directly aligned consumer self-care indication because Canadian antacid products are specifically authorized for relief of heartburn and acid indigestion. Health Canada's labelling standard permits claims relating to heartburn, indigestion, upset stomach and sour stomach associated with excess stomach acid. This broad symptom-oriented positioning supports strong consumer recognition of antacids as readily accessible self-care products.
• Peptic ulcer represents a more medically supervised indication than occasional heartburn. PPIs are authorized in Canada for treatment of peptic ulcers because reducing gastric acid can support ulcer management. However, antacids themselves are not positioned by Health Canada's antacid standard as products for claiming treatment of gastric or intestinal ulcers, highlighting the distinction between symptomatic acid relief and treatment of an underlying ulcer condition.
• Others include acid indigestion, sour stomach, upset stomach and related upper-gastrointestinal discomfort. Canada's regulatory framework explicitly recognizes these symptoms within permitted antacid indications. Combination products can broaden the value proposition further; for example, simethicone-containing products can address gas associated with heartburn or indigestion.

Canada Antacids Market By Distribution Channel
• Retail pharmacies remain a key channel because non-prescription medicines in Canada are generally available for consumer self-selection, although some products may be recommended by healthcare professionals or sold behind the counter. Pharmacy environments also provide consumers with access to pharmacists when they need guidance about selecting between antacids, acid suppressants and other gastrointestinal treatments.
• Hospital pharmacies are more strongly associated with clinically directed gastrointestinal therapy than spontaneous OTC purchasing. They support patients receiving treatment for diagnosed gastrointestinal conditions and patients taking multiple medications, where pharmacists and physicians may need to consider interactions, contraindications and the distinction between symptomatic antacid use and disease-directed therapy.
• Online pharmacies / E-commerce provide Canadian consumers with convenience, product comparison and home delivery, particularly for recurring self-care purchases. However, the Canadian market places significant emphasis on verifying the legitimacy of online pharmacies. Health Canada advises consumers to use Canadian-based pharmacies linked to a physical pharmacy and licensed by the relevant provincial or territorial pharmacy regulator. Health Canada also reports that 74% of Canadian online pharmacy sites source medications from outside Canada, highlighting the importance of regulatory verification when purchasing medicines online.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce